ALX Oncology Reports Q1 2026 Earnings and Clinical Trial Results
ALX Oncology (NASDAQ: ALXO) reported clinical trial results showing promising data for its breast cancer therapy, including a high objective response rate in specific patient subsets. The ASPEN-09 Phase II study is progressing toward interim top-line data by mid-2027.
Tickers: $ALXO
Topics: ASPEN-09 Phase II breast cancer CD47 biomarker ENHERTU (T-DXd) HER2-positive